Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Metrics to compare | ANL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANLPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −1.9x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | 2.2x | 1.9x | 2.6x | |
Price / LTM Sales | - | 10.0x | 3.3x | |
Upside (Analyst Target) | - | 195.4% | 42.8% | |
Fair Value Upside | Unlock | 11.2% | 6.5% | Unlock |